Zentek Ltd Dossier
Qualitative Analysis
Business overview
Zentek Ltd. (TSX-V: ZEN / NASDAQ: ZTEK) is a Canadian-based intellectual property (IP) development and commercialization company focused on next-generation healthcare solutions, advanced materials, and critical minerals. The company's core business model revolves around the research, development, and commercialization of graphene-enabled and advanced nanomaterial technologies. Its flagship proprietary technology is ZenGUARD™, a patent-pending graphene-based antimicrobial coating designed to impart 99% antimicrobial activity to personal protective equipment (PPE) and heating, ventilation, and air conditioning (HVAC) filtration systems. Additionally, Zentek owns a 100% interest in the Albany Graphite Project in Northern Ontario, a principal critical minerals asset being developed for high-purity specialty graphite markets, including battery anodes and nuclear applications. Through its subsidiary Triera Biosciences, the company is also commercializing an aptamer-based platform for rapid detection diagnostics and therapeutics.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Narrowing corporate focus to three core platforms: Albany Graphite, ZenGUARD™, and Triera Biosciences, managed against defined milestones and a 24-month roadmap. Non-core initiatives are paused or wound down to preserve capital.
Expected impact: Rebuilding shareholder value, reducing the cost base, and aligning spending with near-term commercial priorities.
Advancing the Albany Graphite Project toward a Pre-Feasibility Study (PFS) and a new Preliminary Economic Assessment (PEA). This includes launching the Year Two Environmental and Social Baseline Program with ERM and Constance Lake First Nation.
Expected impact: Positioning Albany as a domestic source of nuclear-grade (5N purity) and defence-critical graphite for NATO allied supply chains, opening pathways to non-dilutive government funding.
Commercializing ZenGUARD™ Enhanced Air Filters by integrating the proprietary technology directly into the production lines of established manufacturers rather than building standalone capacity.
Expected impact: Enables rapid, asset-light market entry into the Canadian and U.S. HVAC filtration sectors following Health Canada regulatory classification and the receipt of a key U.S. patent.
Launching Contract Research Organization (CRO) services for custom aptamer discovery, biosensor enablement, and machine-learning classification under an exclusive 20-year McMaster University license.
Expected impact: Establishes a client-funded, IP-ownership revenue engine targeting high-priority infectious disease and oncology detection markets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Serves as the primary launchpad for ZenGUARD™ Enhanced Air Filters in the multi-billion dollar U.S. HVAC market, validating Zentek's asset-light, partnership-driven commercialization model.
Terms: 8-to-12 week pilot program initiated in March 2026 to define the commercial and technical framework for a potential long-term supply arrangement.
Expands the global footprint of ZenGUARD™ Enhanced Air Filters into the Gulf Cooperation Council (GCC) region, supporting regional health, energy efficiency, and advanced materials initiatives.
Terms: Three-year agreement (effective April 11, 2025) with renewal options. Zentek supplies coated filter media, FSCO manufactures and distributes the filters under Zentek's branding, and net sales revenues are shared.
Explores the establishment of a new manufacturing facility in the Middle East, combining Levidian's LOOP carbon capture/graphene production technology with Zentek's materials expertise to scale ZenGUARD™ regional deployment.
Terms: Agreement signed in April 2025 to explore facility development and site selection.
Accelerates commercialization of Zentek's technologies in the U.S., including the ZenGUARD™ platform and a novel Graphite Gel-Based Fire-Retardant (GraphGel™).
Terms: Binding letter of intent signed in September 2025. Altek funds U.S. manufacturing, testing, and commercialization, paying Zentek a royalty of 5% to 8% of net sales for ZenGUARD™ and a royalty on GraphGel™ sales.